The 44-year-old surgeon contracted the Ebola virus while giving treatment to other patients in Sierra Leone. He was taken to Omaha on Saturday in extreme critical conditions, doctors told everyone. Martian Salia succumbed to the disease in the morning around 4 A.M. on Monday.
According to hospital officials, the 36-hour effort to secure the life of Dr. Martin Salia at the Nebraska Medical Centre included a rare dose of the experimental Ebola drug ZMapp.
ZMapp has been proved as one of the unproven medical treatments for every Ebola patient. According to the officials, ZMapp was given round-the-clock to workers to save them from Ebola. However, the second one was a transfusion of blood plasma from an unnamed Ebola survivor.
Even after given amazing care, he progressed to the point of cardiac arrest. The doctors said that they did everything they could to save Mr. Salia. Both the treatments failed to reverse the course of Salia’s illness.
Dr. Daniel Johnson, the hospital critical care director said, “When he arrived, he had no kidney function.” He also added, “He was working extremely hard to breathe and was unresponsive.”
Neither ZMapp nor the transfusion of so-called convalescent plasma has been proven to fight against Ebola in humans. Nevertheless, researchers still believe that they will find out something that will help in fighting against Ebola. They are trying to introduce useful virus-fighting antidotes into a patient’s bloodstream, so that he/she can be cured.
ZMapp was introduced and developed by Mapp Biopharmaceutical Inc. in San Diego, and contains a cocktail of three monoclonal antibodies. The drug is grown in tobacco leaves. It takes months to develop. In August, the company also announced that its supply had been exhausted.